LogicBio Therapeutics Announces SUNRISE Phase 1/2 Clinical Design for LB-001
August 10, 2020
– LogicBio’s First IND Clearance Leveraging GeneRide, an In Vivo Homologous Recombination-based Genome Editing Platform –
– Enrollment to Start with Patients as Young as 3 Years Old, De-escalating Down to 6 Months old –
LogicBio Therapeutics, Inc. (Nasdaq:LOGC) (LogicBio or the Company), a company dedicated to extending the reach of genetic medicine with pioneering targeted delivery platforms, today announced the clinical trial design for the planned Phase 1/2 clinical trial for LB-001 in pediatric patients with methylmalonic acidemia (MMA) .